Clinical Trial Update: Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 study of MDX-1411 for relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma has been withdrawn from the trial program.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma

Drugs mentioned

• MDX-1411

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma. | Phase 1 | Status: WITHDRAWN